Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft‐versus‐host disease by inhibiting T‐cell migration to the gastrointestinal tract

Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft‐versus‐host disease by inhibiting T‐cell migration to the gastrointestinal tract

Abstract Introduction Allogeneic hematopoietic stem cell transplantation (aHSCT) is a curative treatment for hematopoietic malignancies. Graft‐versus‐host disease (GVHD) is a major complication of aHSCT. After transplantation, the balance of immune conditions, such as proinflammatory cytokine level...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Yukie Tsubokura, Hideaki Yoshimura, Atsushi Satake, Yutaro Nasa, Ryohei Tsuji, Tomoki Ito, Shosaku Nomura
Formáid: Alt
Teanga:English
Foilsithe / Cruthaithe: Wiley 2022-09-01
Sraith:Immunity, Inflammation and Disease
Ábhair:
graft‐versus‐host disease
hematopoietic stem cell transplantation
lenalidomide
regulatory T cells
Rochtain ar líne:https://doi.org/10.1002/iid3.688

Ar líne

https://doi.org/10.1002/iid3.688

Míreanna comhchosúla